

The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

904. OUTCOMES RESEARCH-NON-MALIGNANT CONDITIONS

Sickle Cell Disease Births and Social Vulnerability (2016-2020): A Report from the Sickle Cell Data Collection Program

Mariam Kayle, PhD¹, Audrey Blewer, PhD MPH², Wei Pan, PhD³, Jennifer A Rothman, MD⁴, Carri Polick, PhD MPH⁵, Joshua Rivenbark, MD PhD⁶, Elliott Fisher, MS⁷, John J Strouse, MD PhD⁸, Shelby Weeks, MHS⁹, Jay Desai, PhD MPH¹⁰, Angie Snyder, PhD¹¹, Mei Zhou¹², Ankit Sutaria, MBBS, MPH¹³, Sophia Horiuchi, BA¹⁴, Jhaqueline Valle¹⁵, Marci K Sontag, PhD¹⁶, Joshua I Miller¹⁶, Ashima Singh, PhD¹⁷, Mahua Dasgupta, MS¹⁸, Issac A Janson, PhD¹⁹, Najibah Galadanci, MBBS, PhD MPH²⁰, Ayme Miles²¹, Shamaree J Cromartie, MPH²², Sarah L Reeves, PhD²³, Krista Latta, MPH²⁴, William O Cooper²⁵, Allison Plaxco, MPH²⁶, Matthew P Smeltzer, PhD²⁷

¹ School of Nursing, Duke University, Durham, NC

² Duke University School of Nursing and Medicine, Duke University, Durham, NC

³ School of Nursing and School of Medicine, Duke University, Durham, NC

⁴ Duke University Medical Center, Durham, NC

⁵ Duke University School of Nursing; Durham VA Health Care System, Durham, NC

⁶ Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill

⁷ Duke Office of Clinical Research, Duke University School of Medicine, Durham, NC

⁸ Department of Medicine, Division of Hematology, Duke University School of Medicine, Durham, NC

⁹ Division of Public Health, North Carolina Department of Health and Human Services, Raleigh, NC

¹⁰ Minnesota Department of Health, St. Paul, MN

¹¹ Georgia Health Policy Center, Georgia State University, Atlanta, GA

¹² Georgia State University, Georgia Health Policy Center, Atlanta, GA

¹³ Georgia Department of Public Health, Atlanta, GA

¹⁴ Public Health Institute, Tracking California, Richmond, CA

¹⁵ Tracking California, Public Health Institute, Richmond, CA

¹⁶ Center for Public Health Innovation, CI International, Littleton, CO

¹⁷ Department of Pediatrics, Division of Hematology and Oncology, Medical College of Wisconsin, Pewaukee, WI

¹⁸ Medical College of Wisconsin, Milwaukee, WI

¹⁹ Indiana Hemophilia and Thrombosis Center, Indianapolis, IN

²⁰ Department of Medicine/Hematology, University of Alabama at Birmingham, Birmingham, AL

²¹ University of Alabama at Birmingham, Birmingham, AL

²² Virginia Department of Health, Richmond, VA

²³ University of Michigan, Ann Arbor, MI

²⁴ Susan B Meister Child Health Evaluation and Research Center, University of Michigan, Ann Arbor, MI

²⁵ Departments of Pediatrics and Health Policy, Vanderbilt University School of Medicine, Nashville, TN

²⁶ School of Public Health, The University of Memphis, Memphis, TN

²⁷ Division of Epidemiology, Biostatistics and Environmental Health, School of Public Health, University of Memphis, Memphis, TN

Introduction

Despite national implementation of universal newborn screening for sickle cell disease (SCD) since 2006, data on the prevalence of SCD births in the United States are scarce. Updated prevalence data by geographic location are needed to guide the allocation of resources and to connect newborns to comprehensive SCD care. The purposes of this study were to describe the 1) crude and race-adjusted SCD birth prevalence and 2) crude SCD birth prevalence by quartiles of the social vulnerability index (SVI, CDC, 2020) in 11 Sickle Cell Data Collection (SCDC) program states (Alabama, California, Colorado, Georgia, Indiana, Michigan, Minnesota, North Carolina, Tennessee, Virginia, and Wisconsin).

Methods

This retrospective cohort study used newborn screening (NBS) records from 2016 to 2020. Births were included if they were confirmed SCD births and the mother's county of residence at the time of birth was in an SCDC state. Mother's county and newborn's race, ethnicity, sex, date of birth, and genotype were extracted from NBS records or birth certificates, if available. Crude SCD birth prevalence per 10,000 was calculated by dividing the cumulative number of SCD births by the cumulative number of all live births from 2016 to 2020 and multiplying by 10,000. Race-adjusted SCD birth prevalence was calculated by dividing the cumulative number of Black SCD births by live non-Hispanic Black (NHB) births from 2016 to 2020 and multiplying by 10,000. Frequency of all births and NHB births were obtained from each state's health department.

County characteristics were quantified by the SVI using the 2020 state-ranked CDC/ATSDR SVI datasets (CDC, 2020) and were matched to mother's county of residence at birth. SVI ranks counties on 16 social factors, including unemployment, minority status, and disability. Ranks were grouped into SVI quartiles: low ($0 \leq \text{SVI} \leq 0.25$), medium ($0.25 < \text{SVI} \leq 0.5$), high ($0.5 < \text{SVI} \leq 0.75$) and very high ($0.75 < \text{SVI} \leq 1.0$) vulnerability. Crude SCD birth prevalence was calculated for each SVI quartile.

Results

From 2016 through 2020, there were 3,305 newborns with SCD across 11 SCDC states [49.6% male, 89.8% Black]. Georgia had the highest number of births ($n=758$) followed by North Carolina ($n=435$), California ($n=419$), and Alabama ($n=386$). The majority (57.0%) had Hb SS or Hb S Beta⁰ thalassemia, 27.9% had Hb SC, and 9.6 % had Hb S Beta⁺ thalassemia or other SCD type.

The crude SCD birth prevalence ranged from 1.22 to 13.22 per 10,000 live births. The race-adjusted SCD birth prevalence for SCDC states was 28.55 per 10,000 or 1 in every 350 NHB births. Race-adjusted birth prevalence varied among states ranging from 19.53 to 34.11 per 10,000 NHB births (Table 1).

Overall, the majority (67%) of mothers of newborns with SCD resided in high or very high social vulnerability counties (Figure 1). Except for Colorado, where the highest crude SCD birth prevalence was among mothers residing in medium social vulnerability counties, the remaining 10 SCDC states had the highest prevalence among mothers residing in high or very high social vulnerability counties.

Limitations include using the mother's reported race for all births to calculate race-adjusted birth prevalence. Additionally, because of missing data on ethnicity for SCD births, we used all Black SCD births, rather than non-Hispanic Black SCD births, to calculate the race-adjusted SCD birth prevalence. Despite the limitations, the study provides crude and race-adjusted SCD birth prevalence data from 11 states in the South, Midwest, and Western United States, covering an estimated one third of the SCD population in the United States. Furthermore, providing the crude prevalence of SCD births by SVI quartile adds valuable information on county-level characteristics that might influence health outcomes for newborns with SCD.

Conclusions

The race-adjusted birth prevalence for SCD remains stable from previous estimates at 1 in every 350 BNH births. The finding that most mothers of newborns with SCD reside in high and very high social vulnerability counties at the time of birth underscores the importance of assessing social determinants of health (SDOH) that may impact health outcomes for newborns with SCD. Findings from this report can be used to guide state- and county-level programs that address SDOH for people with SCD and have implication for clinicians who must incorporate screening for SDOH in their practice and refer families to community resources as needed.


Disclosures Rothman: Pfizer: Consultancy, Honoraria, Research Funding; Agios Pharmaceuticals, Inc.: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; bluebird bio: Research Funding. **Strouse:** Agios, Takeda, Disc Medicine: Consultancy, Research Funding. **Horiuchi:** Bio-Rad: Current equity holder in publicly-traded company; Natera: Current Employment, Current equity holder in publicly-traded company; Roche: Ended employment in the past 24 months.

Table 1. Crude and Race-Adjusted Sickle Cell Disease (SCD) Birth Prevalence by Sickle Cell Data Collection State and Overall, 2016-2020

State	SCD births (n)	All Live Births (n)	Crude SCD Birth Prevalence*	Black SCD Births (n)	Live non-Hispanic Black births (n)	Race-Adjusted (Black) SCD Birth Prevalence**
Alabama	386	292,038	13.22	312	91,467	34.11
California	419	2,281,910	1.84	374	136,485	27.40
Colorado	66	540,370	1.22	54	17,541	30.08
Georgia	758	633,778	11.96	711	228,199	31.16
Indiana	175	406,382	4.31	144	52,827	27.26
Michigan	315	547,020	5.76	284	107,109	26.52
Minnesota	90	335,154	2.69	85	43,514	19.53
North Carolina	435	595,301	7.31	395	143,595	27.51
Tennessee	224	401,622	5.58	215	81,995	26.22
Virginia	321	493,627	6.50	289	104,973	27.53
Wisconsin	116	319,625	3.63	108	33,073	32.66
<i>Sickle Cell Data Collection States, Total</i>	3,305	6,846,827	4.83	2,971	1,040,778	28.55

*Crude prevalence of SCD births were calculated by dividing the number of SCD births by number of live births in each state during 2016 to 2020 of study multiplied by 10,000.

**Race-adjusted prevalence of Black SCD births was calculated by dividing the number of Black SCD births by number of live non-Hispanic Black births in each state during 2016 to 2020 multiplied by 10,000. Race-adjusted rates for Alabama, Colorado, and Indiana should be interpreted with caution because 13-14% of SCD births in these states had unknown race. The race-adjusted prevalence for these states could be an underestimate of the state's race-adjusted prevalence.



*Alabama had 105 (27.2%) sickle cell births with unknown county, the results for Alabama should be interpreted with caution

Figure 1

<https://doi.org/10.1182/blood-2023-190363>